2 active not recruiting, 1 terminated, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Terminated 1, Withdrawn 1 |
Follow Stage II Hepatocellular Carcinoma AJCC v8: new trials by email Literature Review of Stage II Hepatocellular Carcinoma AJCC v8 trials Research Report on Stage II Hepatocellular Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Durvalumab, Regorafenib - Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8 | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 4 | 2023-07-01 | 2026-07-20 |
| Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Proton Stereotactic Body Radiation Therapy, Quality-of-Life Assessment - Recurrent Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 9 | 2021-08-24 | 2025-12-31 |
| Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery - Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2021-02-10 | 2026-09-14 |
Adenocarcinoma (4) · Carcinoma (4) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Liver Diseases (4) · Liver Neoplasms (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4)
Disulfides (2) · Immunoglobulin G (2) · Bevacizumab (1) · Quality of Life (1) · Radiosurgery (1) · atezolizumab (1) · durvalumab (1) · regorafenib (1)
Academic and Community Cancer Research United (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1)
United States (3)
Ahmed O Kaseb (1) · Jonathan B. Ashman, M.D., Ph.D. (1) · Mehmet Akce (1) · Nima Nabavizadeh (1)
P30CA015083 (1)